Advertisement

BDX

Becton, Dickinson and Company

Healthcare · USD

Set alert

Price alert · BDX

All alert types
197.88 USD -0.46 -0.23%
As of Oct 30, 2026 Extended hours 197.88 0.00%
Bid
197.74 × 100
Ask
197.95 × 100
197.06 Day range 199.94
138.67 52-week range 200.42
YTD
+29.70%
1 year
+40.32%
Open
199.77
Prev close
198.34
Mkt cap
53.90B
Vol
2.92M
Avg vol
1.73M
EPS
4.30
P/E
46.02
Div yield
2.12%
More statistics
Low
197.06
High
199.94
Forward P/E
14.87
Beta
0.28
Short ratio
4.88
Inst. own
99.68%
Dividend
4.20
Ex-div date
Sep 8, 2026
Earnings
Nov 5, 2026
50-d avg
186.39
200-d avg
165.81
1y target
195.57

MAX chart

Chart tools
Interval
BDX all-time price chart0.9857.2113.4169.7225.9Feb 73Nov 83Aug 94May 05Feb 16Oct 26

Key statistics

Market cap
53.88B
Enterprise value
70.12B
Trailing P/E
46.00
Forward P/E
14.87
PEG ratio
1.11
Price / sales
2.40
Price / book
2.21
EPS (TTM)
4.30
Beta
0.28
Dividend yield
2.12%
Payout ratio
72.49%
Profit margin
4.19%
Revenue (TTM)
22.48B
Revenue growth
5.40%
Free cash flow
4.48B
Total cash
709.00M
Total debt
16.81B
Return on equity
6.61%
Shares outstanding
272.39M
Short % of float
3.73%
50-day average
186.39
200-day average
165.81

Analyst view

Consensus: buy

Buy
Price target (mean) 195.57 -1.2% downside
Target (low)
165.00
Target (mean)
195.57
Target (high)
225.00
Ratings (0m) 16 8 buy · 7 hold · 1 sell
  • Strong buy1
  • Buy7
  • Hold7
  • Sell0
  • Strong sell1

Next earnings

Nov 5, 2026

Expected Nov 5, 2026. Consensus EPS estimate 4.07.

Earnings history

Financials — quick view

All financials
BDX Revenue — quarterly 4.98B
2022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 20262026-Q3 2026
BDX Net income — quarterly 377.00M
2022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 20262026-Q3 2026
BDX EPS — quarterly 1.37
2022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 20262026-Q3 2026

Earnings

BDX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 30, 20264.07———
Aug 6, 2026Jun 30, 20263.143.23+0.09+2.87%
May 7, 2026Mar 31, 20262.782.90+0.12+4.32%
Feb 9, 2026Dec 31, 20252.212.91+0.70+31.67%
Nov 6, 2025Sep 30, 20253.923.96+0.04+1.02%
Aug 7, 2025Jun 30, 20253.403.68+0.28+8.24%

Upgrades / downgrades

BDX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 7, 2026Barclaysinit—Underweight
Aug 31, 2026B of A SecuritiesmainNeutralNeutral
Aug 13, 2026RBC CapitalmainSector PerformSector Perform
Aug 7, 2026CitigroupmainBuyBuy
Aug 7, 2026RBC CapitalmainSector PerformSector Perform
Aug 7, 2026Piper SandlermainNeutralNeutral

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States
Website
bd.com

News

Your note

Sign in to keep a note on BDX — it syncs with the Stock Master app.

Insider holders

BDX insider holders
InsiderRelationLatest transactionDateShares held
DELOREFICE CHRISTOPHERChief Financial OfficerStock Award(Grant)Nov 25, 202522,982
FELD MICHAELOfficerSaleOct 25, 202619,568
FRASER CLAIREDirectorSaleSep 9, 202522,226
GOETTE ROLANDOfficerSaleAug 10, 202616,635
JONES CHRISTOPHER IAN MONTAGUEDirectorStock Award(Grant)Jan 26, 202624,304
MUHSIN BILALOfficerStock Award(Grant)Jun 30, 202641,359

Institution ownership

BDX institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.93%24,592,1664.86BJun 29, 2026
Vanguard Capital Management LLC6.53%17,987,8343.56BJun 29, 2026
State Street Corporation5.44%15,000,0642.97BJun 29, 2026
Vanguard Portfolio Management LLC5.43%14,974,1362.96BJun 29, 2026
First Eagle Investment Management, LLC5.01%13,815,3352.73BJun 29, 2026
Invesco Ltd.3.23%8,898,4881.76BJun 29, 2026

Fund ownership

BDX fund ownership
Holder% heldSharesValueReported
First Eagle Funds-First Eagle Global Fund3.32%9,151,9951.81BJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%8,747,2611.73BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%7,136,0261.41BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund2.17%5,970,1671.18BJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.32%3,629,584717.97MSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%3,576,755707.52MAug 30, 2026
Advertisement